SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001828185-24-000017
Filing Date
2024-03-22
Accepted
2024-03-22 08:36:00
Documents
14
Period of Report
2024-05-10

Document Format Files

Seq Description Document Type Size
1 DEF 14A brns-2023xdef14a.htm DEF 14A 780537
2 graphv3a.jpg GRAPHIC 55767
3 image.jpg GRAPHIC 17312
4 image_0.jpg GRAPHIC 187
5 image_1.jpg GRAPHIC 149
6 image_122.jpg GRAPHIC 135
7 image_25a.jpg GRAPHIC 254
8 image_59.jpg GRAPHIC 123
9 image_71.jpg GRAPHIC 154
10 image_8.jpg GRAPHIC 129
11 image_95.jpg GRAPHIC 146
12 picture1a.jpg GRAPHIC 150153
13 proxycard2024a.jpg GRAPHIC 140996
14 proxyinstructions2024a.jpg GRAPHIC 96312
  Complete submission text file 0001828185-24-000017.txt   1419182
Mailing Address UNIT 6-10, ZEUS BUILDING RUTHERFORD AVENUE, HARWELL DIDCOT X0 OX11 0DF
Business Address UNIT 6-10, ZEUS BUILDING RUTHERFORD AVENUE, HARWELL DIDCOT X0 OX11 0DF 44 (0) 1865 818808
Barinthus Biotherapeutics plc. (Filer) CIK: 0001828185 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40367 | Film No.: 24773203
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)